| Symbol | SLNCF |
|---|---|
| Name | SILENCE THERAPEUTICS, PLC. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | W14 8TH United Kingdom 72 Hammersmith Road |
| Telephone | 44 20 3457 6900 |
| Fax | — |
| — | |
| Website | http://www.silence-therapeutics.com |
| Incorporation | GB |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001479615 |
| Description | Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical needs. Its income consists of royalty income and revenue from collaboration agreements. Its geographical segments are the United Kingdom, the United States, and Germany. Additional info from NASDAQ: |
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Read moreSilence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Read moreSilence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Read moreREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
Read moreSilence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Read moreSilence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Read moreSilence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
Read moreSilence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera | Phase1 | Polycythemia Vera | Active_Not_Recruiting | 2023-01-26 | 2030-03-01 | ClinicalTrials.gov |
| NCT05537571 | Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of At… | Phase2 | Cardiovascular Diseases | Completed | 2022-12-13 | 2024-07-01 | ClinicalTrials.gov |
| NCT04718844 | A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodyna… | Phase1 | Non-transfusion-dependent Thalassemia | Completed | 2021-04-14 | 2023-05-23 | ClinicalTrials.gov |
| NCT04606602 | Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subj… | Phase1 | Hyperlipidemias | Completed | 2020-11-18 | 2023-08-23 | ClinicalTrials.gov |
| NCT04559971 | A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in He… | Early_Phase1 | Healthy Volunteers | Completed | 2020-09-03 | 2021-03-23 | ClinicalTrials.gov |
| NCT04176653 | Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate … | Phase1 | Non-transfusion-dependent Thalassemia | Withdrawn | 2019-08-20 | 2021-10-14 | ClinicalTrials.gov |
| NCT01808638 | Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-0… | Phase1 | Carcinoma, Pancreatic Ductal | Completed | 2013-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT00938574 | Study With Atu027 in Patients With Advanced Solid Cancer | Phase1 | Advanced Solid Tumors | Completed | 2009-06-01 | 2012-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Non-transfusion-dependent Thalassemia | COMPLETED | NCT04718844 |
| SLN124 | Other | Phase PHASE1 | Non-transfusion-dependent Thalassemia | COMPLETED | NCT04718844 |
| Placebo | Other | Phase PHASE1 | Hyperlipidemias | COMPLETED | NCT04606602 |
| SLN360 | Other | Phase PHASE1 | Hyperlipidemias | COMPLETED | NCT04606602 |
| Placebo | Other | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT05537571 |
| SLN360 | Other | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT05537571 |
| Atu027 & gemcitabine in treatment arm 2 | Drug | Phase PHASE1 | Carcinoma, Pancreatic Ductal | COMPLETED | NCT01808638 |
| Atu027 & gemcitabine in treatment arm 1 | Drug | Phase PHASE1 | Carcinoma, Pancreatic Ductal | COMPLETED | NCT01808638 |
| Atu027 & gemcitabine in lead in safety period | Other | Phase PHASE1 | Carcinoma, Pancreatic Ductal | COMPLETED | NCT01808638 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Other | Phase PHASE1 | Non-transfusion-dependent Thalassemia | WITHDRAWN | NCT04176653 |
| Placebo | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT04559971 |
| SLN124 | Other | Phase EARLY_PHASE1 | Healthy Volunteers | COMPLETED | NCT04559971 |
| Placebo | Other | Phase PHASE1 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05499013 |
| SLN124 | Other | Phase PHASE1 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05499013 |
| SLN360 | DRUG | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT05537571 |
| Placebo | DRUG | Phase PHASE2 | Cardiovascular Diseases | COMPLETED | NCT05537571 |
| SLN124 | DRUG | Phase PHASE1 | Polycythemia Vera | ACTIVE_NOT_RECRUITING | NCT05499013 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | DRUG | Phase PHASE1 | Non-transfusion-dependent Thalassemia | WITHDRAWN | NCT04176653 |